Scientists have developed a new insulin molecule that responds to the blood glucose levels of rats, which they believe may help patients with type 1 diabetes.
Scientists have developed a glucose-responsive insulin (GRI) molecule that they believe could revolutionize the treatment of type 1 diabetes. The study was conducted at the University of Copenhagen in Denmark and the biotechnology company Gubra.
According to the team, the insulin on the market is not able to determine whether a patient with type 1 diabetes needs little or much of the effect of insulin, which lowers blood sugar.
“That’s why we’ve taken the first step towards a type of insulin that can adjust itself depending on the patient’s blood sugar level. This has great potential to significantly improve the lives of people with type 1 diabetes, ‘explained Professor Knud Jensen, one of the researchers.
Scientists have developed glucose-cleavable linkers based on the hydrazone and thiazolidine structures. They created connectors with low levels of spontaneous hydrolysis but increased levels of hydrolysis as glucose levels increased, allowing them to sense how much glucose would be in the body. Although it continuously releases a certain amount of insulin as blood sugar levels rise, the molecule becomes more active and releases more insulin. When blood sugar levels drop, less is released. By studying the molecule in rats, scientists found it to be effective.
The researchers explain that lipidated hydrazones and thiazolidines were linked to the LysB29 HI side chain via pH-controlled acylations, providing a glucose responsive GRI. in vitro for thiazolidines. Clamp studies showed increased glucose infusion under hyperglycemic conditions for one GRI indicative of a true glucose response.
A glucose-responsive cleavage linker in these GRIs allowed for changes in glucose levels to direct the release of active insulin.
“It will provide patients with type 1 diabetes with safer and easier treatment. Today, a person with type 1 diabetes has to inject themselves with insulin multiple times a day and monitor their blood sugar frequently by pricking their finger with a blood glucose meter. As a result, a person can inject a new insulin molecule less often during the day and thus think less about it, ”said Jensen.
The results were published in Chemistry Europe.